Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics
A priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.